ID

37149

Description

Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT02404558

Link

https://clinicaltrials.gov/show/NCT02404558

Keywords

Versions (1)
  1. 7/4/19 7/4/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 4, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Rheumatoid Arthritis NCT02404558

English

Eligibility Rheumatoid Arthritis NCT02404558

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with rheumatoid arthritis (ra) as defined by the american college of rheumatology (acr)/european league against rheumatism (eular) 2010
Description

Rheumatoid Arthritis

Data type

boolean

Alias
UMLS CUI [1]
C0003873
rheumatoid arthritis classification criteria.
Description

Rheumatoid Arthritis Classification criteria

Data type

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0008902
UMLS CUI [1,3]
C0243161
acr class i-iii functional status, based on the 1991 revised criteria.
Description

Rheumatoid Arthritis Functional Status Class

Data type

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0598463
UMLS CUI [1,3]
C0456387
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients less than 20 years of age.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
prior treatment with any biologic anti-interleukin-6 (anti-il-6) or interleukin-6 receptor (il-6r) antagonist.
Description

Interleukin-6 Antagonist | Interleukin-6 Receptor Antagonist

Data type

boolean

Alias
UMLS CUI [1]
C3864917
UMLS CUI [2]
C3819026
any parenteral or intraarticular glucocorticoid injection within 4 weeks prior to randomization.
Description

Glucocorticoid Parenteral Injection | Glucocorticoid Intra-Articular Injection

Data type

boolean

Alias
UMLS CUI [1,1]
C0017710
UMLS CUI [1,2]
C1555373
UMLS CUI [2,1]
C0017710
UMLS CUI [2,2]
C0021488
treatment with prednisone higher than 10 mg or equivalent per day, or change in dosage within 4 weeks prior to randomization.
Description

Prednisone U/day | Equivalent U/day | Prednisone Dosage Change

Data type

boolean

Alias
UMLS CUI [1,1]
C0032952
UMLS CUI [1,2]
C0456683
UMLS CUI [2,1]
C0205163
UMLS CUI [2,2]
C0456683
UMLS CUI [3,1]
C0032952
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0392747
treatment with disease-modifying antirheumatic drugs (dmards), immunosuppressive agents, tumor necrosis factor (tnf) antagonists or any other ra-directed biologic agents within a certain amount of time prior to randomization.
Description

DMARDs | Immunosuppressive Agents | TNF-inhibitors | Biological agents Targeting Rheumatoid Arthritis

Data type

boolean

Alias
UMLS CUI [1]
C0242708
UMLS CUI [2]
C0021081
UMLS CUI [3]
C3653350
UMLS CUI [4,1]
C0005515
UMLS CUI [4,2]
C1521840
UMLS CUI [4,3]
C0003873
participation in any clinical research study that evaluated an investigational drug or therapy within 5 half-lives or 60 days of the screening visit, whichever is longer.
Description

Study Subject Participation Status | Investigational New Drugs | Therapies, Investigational

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
UMLS CUI [3]
C0949266
active or suspected tuberculosis (tb) or at high risk of contracting tb.
Description

Tuberculosis | Tuberculosis Suspected | High risk of Tuberculosis

Data type

boolean

Alias
UMLS CUI [1]
C0041296
UMLS CUI [2,1]
C0041296
UMLS CUI [2,2]
C0750491
UMLS CUI [3,1]
C0332167
UMLS CUI [3,2]
C0041296
fever, or chronic, persistent, or recurring infection(s) requiring active treatment.
Description

Fever Treatment required for | Chronic infectious disease Treatment required for | Persistent infection Treatment required for | Recurrent infections Treatment required for

Data type

boolean

Alias
UMLS CUI [1,1]
C0015967
UMLS CUI [1,2]
C0332121
UMLS CUI [2,1]
C0151317
UMLS CUI [2,2]
C0332121
UMLS CUI [3,1]
C1264606
UMLS CUI [3,2]
C0332121
UMLS CUI [4,1]
C0239998
UMLS CUI [4,2]
C0332121
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Description

Study Subject Participation Status Consideration Additional

Data type

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C0518609
UMLS CUI [1,3]
C1524062
Back to the top of the page

Similar models

Eligibility Rheumatoid Arthritis NCT02404558

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Rheumatoid Arthritis
Item
patients with rheumatoid arthritis (ra) as defined by the american college of rheumatology (acr)/european league against rheumatism (eular) 2010
boolean
C0003873 (UMLS CUI [1])
Rheumatoid Arthritis Classification criteria
Item
rheumatoid arthritis classification criteria.
boolean
C0003873 (UMLS CUI [1,1])
C0008902 (UMLS CUI [1,2])
C0243161 (UMLS CUI [1,3])
Rheumatoid Arthritis Functional Status Class
Item
acr class i-iii functional status, based on the 1991 revised criteria.
boolean
C0003873 (UMLS CUI [1,1])
C0598463 (UMLS CUI [1,2])
C0456387 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Age
Item
patients less than 20 years of age.
boolean
C0001779 (UMLS CUI [1])
Interleukin-6 Antagonist | Interleukin-6 Receptor Antagonist
Item
prior treatment with any biologic anti-interleukin-6 (anti-il-6) or interleukin-6 receptor (il-6r) antagonist.
boolean
C3864917 (UMLS CUI [1])
C3819026 (UMLS CUI [2])
Glucocorticoid Parenteral Injection | Glucocorticoid Intra-Articular Injection
Item
any parenteral or intraarticular glucocorticoid injection within 4 weeks prior to randomization.
boolean
C0017710 (UMLS CUI [1,1])
C1555373 (UMLS CUI [1,2])
C0017710 (UMLS CUI [2,1])
C0021488 (UMLS CUI [2,2])
Prednisone U/day | Equivalent U/day | Prednisone Dosage Change
Item
treatment with prednisone higher than 10 mg or equivalent per day, or change in dosage within 4 weeks prior to randomization.
boolean
C0032952 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
C0205163 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
C0032952 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0392747 (UMLS CUI [3,3])
DMARDs | Immunosuppressive Agents | TNF-inhibitors | Biological agents Targeting Rheumatoid Arthritis
Item
treatment with disease-modifying antirheumatic drugs (dmards), immunosuppressive agents, tumor necrosis factor (tnf) antagonists or any other ra-directed biologic agents within a certain amount of time prior to randomization.
boolean
C0242708 (UMLS CUI [1])
C0021081 (UMLS CUI [2])
C3653350 (UMLS CUI [3])
C0005515 (UMLS CUI [4,1])
C1521840 (UMLS CUI [4,2])
C0003873 (UMLS CUI [4,3])
Study Subject Participation Status | Investigational New Drugs | Therapies, Investigational
Item
participation in any clinical research study that evaluated an investigational drug or therapy within 5 half-lives or 60 days of the screening visit, whichever is longer.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0949266 (UMLS CUI [3])
Tuberculosis | Tuberculosis Suspected | High risk of Tuberculosis
Item
active or suspected tuberculosis (tb) or at high risk of contracting tb.
boolean
C0041296 (UMLS CUI [1])
C0041296 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0332167 (UMLS CUI [3,1])
C0041296 (UMLS CUI [3,2])
Fever Treatment required for | Chronic infectious disease Treatment required for | Persistent infection Treatment required for | Recurrent infections Treatment required for
Item
fever, or chronic, persistent, or recurring infection(s) requiring active treatment.
boolean
C0015967 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
C0151317 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
C1264606 (UMLS CUI [3,1])
C0332121 (UMLS CUI [3,2])
C0239998 (UMLS CUI [4,1])
C0332121 (UMLS CUI [4,2])
Study Subject Participation Status Consideration Additional
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1,1])
C0518609 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial